TABLE 2.
Neutralization of HIV-1 by MAbs and CD4-based molecules in PBMC
| Cells | ID50 (μg/ml)a
|
||||||
|---|---|---|---|---|---|---|---|
| 2F5 | 2G12 | sCD4 | CD4-IgG2 | 15e | 447-52D | 19b | |
| CCR5 primary | |||||||
| SF162 | 11.6 | 0.03 | 5.99 | 0.67 | 49 | 8.1 | 24.6 |
| JR-FL | 1.74 | 0.01 | 20.1 | 0.13 | >50 | ND | >50 |
| Case B2-6-92 | 4.7 | >50 | >50 | 1.83 | >50 | ND | >50 |
| ADA | 6.6 | <0.08 | 29.1 | 0.12 | >50 | ND | ND |
| CCR5 + CXCR4 primary | |||||||
| DH123 | >50 | 5.8 | 25.6 | 0.4 | >50 | ND | >50 |
| 2076 cl1 | 26.7 | 0.18 | >50 | 28.3 | >50 | ND | NB |
| P17 | 14.4 | 0.07 | 19.6 | 1.55 | ND | ND | NB |
| Case B5/86 | 4.88 | 0.03 | >50 | >50 | NB | >50 | NB |
| 89.6 | 12.7 | 0.002 | 1.04 | 0.21 | >50 | ND | >50 |
| CXCR4 primary | |||||||
| HC7 | 22.2 | <0.004 | 27.8 | 0.76 | ND | ND | >50 |
| 2075 | 18.9 | 6.7 | 17.3 | 0.91 | >50 | ND | NB |
| 2044 | 26.3 | >50 | >50 | 8.45 | >50 | >50 | NB |
| 2005 cl1 | >50 | 0.01 | >50 | 0.91 | >50 | ND | NB |
| ACH-P | 8.09 | 0.008 | 34.4 | 2.3 | >50 | 18.1 | ND |
| CCR5 + CXCR4 TCLA | |||||||
| SF2 | 0.07 | 0.003 | 0.14 | 0.06 | 0.32 | <0.08 | 3.21 |
| C17 | 7.8 | 0.008 | 24.9 | 0.22 | ND | ND | NB |
| CXCR4 TCLA | |||||||
| NL4-3 | 1.98 | 0.002 | 0.18 | 0.06 | >50 | ND | >50 |
| ACH-H9 | 1.54 | 0.05 | 0.31 | 0.01 | >50 | ND | ND |
| ACH-P/H9 | 1.23 | 0.013 | 5.3 | 0.2 | >50 | 30.7 | ND |
a
Derived from one representative experiment out of two to five performed. When no neutralization at 50 μg/ml was observed, a value >50 μg/ml is reported. ND, not done; NB, no binding (i.e., neutralization activity could not be evaluated because the MAb epitope is absent from the viral glycoprotein).